

## Solomon Islands Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Solomon Islands					
<b>2. Grant number:</b> 1520-SLB-12c-X / 15-SLB-08c-Y					
<b>3. Date of Decision Letter:</b> 13 December 2017					
<b>4. Date of the Partnership Framework Agreement:</b> 29 April 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2015 -2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)					
	<b>2015-2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	646,500 <sup>3</sup>	130,500	104,500	96,500	978,000
<b>10. Vaccine introduction grant (in US\$):</b> a VIG of US\$100,000 was disbursed on 25 <sup>th</sup> July 2014					
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>4</sup>					
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2015-2017</b>	<b>2018</b>			
Number of Pneumococcal vaccines doses		33,400			
Annual Amounts (US\$)	646,500 <sup>5</sup>	130,500			
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>13. Self-procurement:</b> Not applicable.					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:** Reference code: 1520-SLB-12c-X-C

According to the co-financing policy, the Country falls within the Accelerated Transition group, as of 1 January 2017.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	26,200	31,800	43,400
Number of AD syringes	27,500		
Number of re-constitution syringes			
Number of safety boxes	325		
Value of vaccine doses (US\$)	86,336		
Total co-financing payments (US\$) (including freight)	90,500	110,000	150,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**  
 Hind Khatib-Othman  
 Managing Director, Country Programmes  
 13 December 2017